Biogen Inc. (BIIB) stock analysis

In our weekly check, Biogen Inc. is graded C (A to F). Of 24 checks on debt, profit, cash flow and trend: 12 pass, warnings: 7, red flags: 5.

About Biogen Inc.

Biogen Inc. is a Healthcare company (Drug Manufacturers - General) based in the United States, listed on NASDAQ as BIIB.

What our checks show for BIIB

Red flags

Warning signs

Strengths

Next earnings report: 2027-02-05

Similar companies

GSK · SNY · BMY · PFE · NVO · GILD

Questions

What grade does Biogen Inc. (BIIB) have?

In our weekly check, Biogen Inc. is graded C (A to F). Of 24 checks on debt, profit, cash flow and trend: 12 pass, warnings: 7, red flags: 5. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of BIIB stock?

This week's biggest flags for Biogen Inc.: Margins falling, Gross margin falling, Thin margins. In total 12 of 24 checks show a warning or a red flag.

What does Biogen Inc. do?

Biogen Inc. is a Healthcare company (Drug Manufacturers - General) based in the United States, listed on NASDAQ as BIIB.

When does Biogen Inc. report earnings next?

The next earnings report is expected on 2027-02-05. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis